What question did this study set out to answer?

To assess the efficacy of DFMO combined with AMXT-1501 compared to DFMO alone in treating relapsed or refractory high-risk pediatric tumors.

Abstract CT270: Clinical trial in progress: BCC020 a dose escalation study using difluoromethylornithine (DFMO) and AMXT-1501 followed by a randomized controlled trial of DFMO with or without AMXT-1501 for neuroblastoma, CNS tumors, and sarcomas

View Full Paper

Ask AI

Bookmark

Authors

Multicenter trial evaluates DFMO plus AMXT-1501 efficacy in pediatric tumors, indicating a novel therapeutic option.

To assess the efficacy of DFMO combined with AMXT-1501 compared to DFMO alone in treating relapsed or refractory high-risk pediatric tumors.
Conducting an open-label multicenter trial for high-risk neuroblastoma and CNS tumors.
Using a 3+3 dose escalation design in Phase I with up to 24 cycles of AMXT-1501 and DFMO.
Randomizing neuroblastoma subjects to receive either the combination therapy or DFMO alone in Phase II.
Combination therapy shows promise in increasing progression-free survival compared to DFMO alone.
Significant antitumor activity observed in DIPG models with DFMO and AMXT-1501.
Projected enrollment of 206 evaluable subjects across various pediatric tumor types.

Sholler et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark